PETER GOLDEN: Open Payments
NPI 1588867626 · AKRON, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,213 in 309 payments from 19 companies in 2025. Trend: 2023 $2,917 · 2024 $4,804 · 2025 $5,213
Food & beverage: $5,102Education: $111
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 62 | $1,278 |
| E.R. Squibb & Sons, L.L.C. | 31 | $597 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 30 | $382 |
| Alkermes, Inc. | 22 | $357 |
| ABBVIE INC. | 26 | $348 |
| Supernus Pharmaceuticals, Inc. | 35 | $328 |
| Teva Pharmaceuticals USA, Inc. | 7 | $320 |
| Neurocrine BioSciences, Inc. | 8 | $273 |
| Vanda Pharmaceuticals Inc. | 13 | $235 |
| Lundbeck LLC | 11 | $210 |
Products named: REXULTI, COBENFY, CAPLYTA, VRAYLAR, Qelbree, ARISTADA, INGREZZA, ABILIFY ASIMTUFII.
Industry payments across OH — which companies pay providers there.
